1552300-77-2

Upstream product

• 1552300-18-1 3-bromo-N-cyclopentyl-6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-methylpyridin-4-amine 
• 1552300-15-8 3-bromo-6-(2,5-dimethyl-1H-pyrrol-1-yl)-4-iodo-2-methylpyridine 
• 1541125-83-0 3-bromo-6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-methylpyridine 
• 1552300-36-3 7-amino-1-cyclopentyl-5-methyl-1,6-naphthyridin-2(1H)-one 
• 1552300-29-4 1-cyclopentyl-7-(2,5-dimethyl-1H-pyrrol-1-yl)-5-methyl-1,6-naphthyridin-2(1H)-one 
• 1552301-08-2 3-fluoro-N-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)benzenesulfonamide 
• 1552300-42-1 7-amino-3-bromo-1-cyclopentyl-5-methyl-1,6-naphthyridin-2(1H)-one 
• 1552300-23-8 (E)-ethyl 3-(4-(cyclopentylamino)-6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-methylpyridin-3-yl)acrylate 

Relevant academic research and scientific papers

Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors

Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway is one of the most intensively studied approaches to cancer therapy. Rational design led to the identification of novel 7-amino-5-methyl-1,6-naph